Chemoprevention of mouse lung and colon tumors by suberoylanilide hydroxamic acid and atorvastatin

Atorvastatin and suberoylanilide hydroxamic acid (SAHA) were evaluated for chemoprevention of mouse lung tumors. In Experiment 1, lung tumors were induced by vinyl carbamate in strain A/J mice followed by 500 mg/kg SAHA, 60 or 180 mg/kg atorvastatin, and combinations containing SAHA and atorvastatin administered in their diet. SAHA and both combinations, but not atorvastatin, decreased the multiplicity of lung tumors, including large adenomas and adenocarcinomas with the combinations demonstrating the greatest efficacy. In Experiment 2, lung tumors were induced by 4‐(methylnitrosoamino)‐1‐(3‐pyridyl)‐1‐butanol in strain A/J mice followed by 180 mg/kg atorvastatin, 500 mg/kg SAHA, or both drugs administered in the diet. SAHA and the combination of both drugs, but not atorvastatin alone, decreased the multiplicity of lung tumors and large tumors, with the combination demonstrating greater efficacy. In Experiment 3, lung tumors were induced by 1,2‐dimethylhydrazine in Swiss‐Webster mice followed by 160 mg/kg atorvastatin, 400 mg/kg SAHA, or a combination of both drugs administered in the diet. SAHA and the combination, but not atorvastatin, decreased the multiplicity of lung tumors with the combination demonstrating greater efficacy. The multiplicity of colon tumors was decreased by SAHA, atorvastatin, and the combination, without any significant difference in their efficacy. mRNA expression analysis of lung tumor bearing mice suggested that the enhanced chemopreventive activity of the combination is related to atorvastatin modulation of DNA repair, SAHA modulation of angiogenesis, and both drugs modulating invasion and metastasis pathways. Atorvastatin demonstrated chemoprevention activity as indicated by the enhancement of the efficacy of SAHA to prevent mouse lung tumors.

[1]  R. Benya,et al.  Randomized Phase II Trial of Sulindac, Atorvastatin, and Prebiotic Dietary Fiber for Colorectal Cancer Chemoprevention , 2011, Cancer Prevention Research.

[2]  S. Hecht,et al.  Inhibition of lung carcinogenesis and critical cancer-related signaling pathways by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-l-cysteine, indole-3-carbinol and myo-inositol, alone and in combination. , 2010, Carcinogenesis.

[3]  W. Woodward,et al.  Suberoylanilide hydroxamic acid blocks self‐renewal and homotypic aggregation of inflammatory breast cancer spheroids , 2010, Cancer.

[4]  Carol Coupland,et al.  Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database , 2010, BMJ : British Medical Journal.

[5]  P. Higgins,et al.  Atorvastatin Induces Apoptosis In Vitro and Slows Growth of Tumor Xenografts but Not Polyp Formation in Min Mice , 2010, Digestive Diseases and Sciences.

[6]  W. Gerald,et al.  Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. , 2009, American journal of translational research.

[7]  Chung S Yang,et al.  Combination regimen with statins and NSAIDs: A promising strategy for cancer chemoprevention , 2008, International journal of cancer.

[8]  Hui You,et al.  Synergistic Inhibition of Lung Tumorigenesis by a Combination of Green Tea Polyphenols and Atorvastatin , 2008, Clinical Cancer Research.

[9]  H. Behlouli,et al.  Statins and cancer risk. , 2008, The American journal of medicine.

[10]  V. Steele,et al.  Modulation by bexarotene of mRNA expression of genes in mouse lung tumors , 2008, Molecular carcinogenesis.

[11]  B. Sternfeld,et al.  Statin Use and Risk of Prostate Cancer in the California Men's Health Study Cohort , 2007, Cancer Epidemiology Biomarkers & Prevention.

[12]  Hermann Brenner,et al.  Individual and joint use of statins and low‐dose aspirin and risk of colorectal cancer: A population‐based case–control study , 2007, International journal of cancer.

[13]  A. Conney,et al.  Atorvastatin and Celecoxib Inhibit Prostate PC-3 Tumors in Immunodeficient Mice , 2007, Clinical Cancer Research.

[14]  V. Steele,et al.  Modulation by budesonide of DNA methylation and mRNA expression in mouse lung tumors , 2006, International journal of cancer.

[15]  V. Steele,et al.  Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (ZarnestraMT). , 2007, Carcinogenesis.

[16]  V. Steele,et al.  Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. , 2006, Cancer research.

[17]  V. Steele,et al.  Prevention of mouse lung tumors by targretin , 2006, International journal of cancer.

[18]  V. Steele,et al.  Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. , 2006, Cancer research.

[19]  R. Lubet,et al.  CHEMOPREVENTION: MOUSE COLON AND LUNG TUMOR BIOASSAY AND MODULATION OF DNA METHYLATION AS A BIOMARKER , 2005, Experimental lung research.

[20]  S. Amin,et al.  Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice. , 2003, Anticancer research.

[21]  V. Steele,et al.  Effect of budesonide on the methylation and mRNA expression of the insulin‐like growth factor 2 and c‐myc genes in mouse lung tumors , 2002, Molecular carcinogenesis.

[22]  S. Hecht,et al.  Inhibition of lung tumorigenesis in A/J mice by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-L-cysteine and myo-inositol, individually and in combination. , 2002, Carcinogenesis.

[23]  V. Steele,et al.  Prevention of mouse lung tumors by budesonide and its modulation of biomarkers. , 2002, Carcinogenesis.

[24]  P. Marks,et al.  Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. , 2002, Anticancer research.

[25]  L. Devy,et al.  Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling , 2002, Oncogene.

[26]  S. De Flora,et al.  Interactions between N‐acetylcysteine and ascorbic acid in modulating mutagenesis and carcinogenesis , 2000, International journal of cancer.

[27]  V. Steele,et al.  Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. , 2000, Carcinogenesis.

[28]  P. Marks,et al.  Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). , 1999, Anticancer research.

[29]  H. Witschi,et al.  Chemoprevention of tobacco smoke-induced lung tumors in A/J strain mice with dietary myo-inositol and dexamethasone. , 1999, Carcinogenesis.

[30]  G. Stoner,et al.  Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin. , 1996, Cancer letters.

[31]  E. Wynder,et al.  Effects of 1,4-phenylenebis(methylene)selenocyanate, phenethyl isothiocyanate, indole-3-carbinol, and d-limonene individually and in combination on the tumorigenicity of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung. , 1996, Anticancer research.

[32]  V. Steele,et al.  Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: Methods and results from the NCI chemoprevention drug development program , 1994, Journal of cellular biochemistry. Supplement.

[33]  R. Estensen,et al.  Studies of chemopreventive effects of myo-inositol on benzo[a]pyrene-induced neoplasia of the lung and forestomach of female A/J mice. , 1993, Carcinogenesis.